Arax Advisory Partners’s Colgate-Palmolive CL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.02M | Buy |
65,662
+39,249
| +149% | +$3.43M | 0.04% | 431 |
|
|
2026
Q1 | $2.25M | Buy |
26,413
+18,893
| +251% | +$1.68M | 0.06% | 247 |
|
|
2025
Q4 | $594K | Sell |
7,520
-6,431
| -46% | -$504K | 0.02% | 537 |
|
|
2025
Q3 | $1.12M | Buy |
13,951
+10,888
| +355% | +$929K | 0.02% | 613 |
|
|
2025
Q2 | $383K | Buy |
3,063
+1,206
| +65% | +$110K | 0.02% | 464 |
|
|
2025
Q1 | $174K | Buy |
1,857
+416
| +29% | +$37.2K | 0.01% | 565 |
|
|
2024
Q4 | $131K | Sell |
1,441
-100
| -6% | -$9.54K | 0.01% | 597 |
|
|
2024
Q3 | $160K | Buy |
1,541
+222
| +17% | +$22.6K | 0.01% | 388 |
|
|
2024
Q2 | $128K | Buy |
1,319
+343
| +35% | +$31.6K | 0.01% | 425 |
|
|
2024
Q1 | $87.9K | Buy |
976
+320
| +49% | +$27.1K | 0.01% | 406 |
|
|
2023
Q4 | $52.3K | Buy |
656
+1
| +0.2% | +$75 | 0.01% | 467 |
|
|
2023
Q3 | $46.6K | Buy |
655
+15
| +2% | +$1.12K | 0.01% | 473 |
|
|
2023
Q2 | $49.3K | Buy |
640
+3
| +0.5% | +$232 | 0.01% | 467 |
|
|
2023
Q1 | $47.8K | Sell |
637
-5
| -0.8% | -$372 | 0.01% | 469 |
|
|
2022
Q4 | $50.6K | Buy |
642
+10
| +2% | +$750 | 0.01% | 445 |
|
|
2022
Q3 | $44K | Hold |
632
| – | – | 0.01% | 448 |
|
|
2022
Q2 | $51K | Buy |
632
+28
| +5% | +$2.19K | 0.01% | 421 |
|
|
2022
Q1 | $46K | Sell |
604
-654
| -52% | -$51.8K | 0.01% | 466 |
|
|
2021
Q4 | $107K | Buy |
1,258
+4
| +0.3% | +$312 | 0.01% | 332 |
|
|
2021
Q3 | $95K | Buy |
1,254
+3
| +0.2% | +$238 | 0.01% | 338 |
|
|
2021
Q2 | $102K | Buy |
+1,251
| New | +$102K | 0.01% | 330 |
|
|
2020
Q4 | $115K | Buy |
1,346
+3
| +0.2% | +$248 | 0.02% | 276 |
|
|
2020
Q3 | $104K | Buy |
1,343
+4
| +0.3% | +$305 | 0.02% | 264 |
|
|
2020
Q2 | $98K | Buy |
1,339
+3
| +0.2% | +$213 | 0.02% | 262 |
|
|
2020
Q1 | $89K | Sell |
1,336
-3,105
| -70% | -$219K | 0.02% | 249 |
|
|
2019
Q4 | $306K | Buy |
4,441
+4
| +0.1% | +$273 | 0.09% | 98 |
|
|
2019
Q3 | $326K | Buy |
4,437
+4
| +0.1% | +$290 | 0.1% | 90 |
|
|
2019
Q2 | $318K | Buy |
+4,433
| New | +$315K | 0.11% | 87 |
|
|
2018
Q4 | $263K | Buy |
4,425
+1,950
| +79% | +$122K | 0.1% | 99 |
|
|
2018
Q3 | $166K | Buy |
2,475
+939
| +61% | +$62.5K | 0.07% | 133 |
|
|
2018
Q2 | $99K | Sell |
1,536
-590
| -28% | -$38.6K | 0.04% | 156 |
|
|
2018
Q1 | $152K | Sell |
2,126
-711
| -25% | -$51.2K | 0.08% | 102 |
|
|
2017
Q4 | $214K | Sell |
2,837
-497
| -15% | -$36.3K | 0.09% | 88 |
|
|
2017
Q3 | $242K | Buy |
3,334
+249
| +8% | +$17.9K | 0.12% | 74 |
|
|
2017
Q2 | $228K | Buy |
3,085
+740
| +32% | +$54.9K | 0.11% | 80 |
|
|
2017
Q1 | $171K | Buy |
2,345
+325
| +16% | +$22.8K | 0.08% | 80 |
|
|
2016
Q4 | $132K | Buy |
+2,020
| New | +$139K | 0.07% | 90 |
|
Other funds holding CL
Arax Advisory Partners's CL Position: Q2 2026 in Review
Arax Advisory Partners increased its Colgate-Palmolive (CL) stake by 149% in Q2 2026, buying an estimated $3.43M and bringing the position to 65,662 shares worth $6.02M. The position accounts for 0.04% of the portfolio, ranked #431.
Arax Advisory Partners first reported a position in CL in Q4 2016 and has held it in 37 quarters since. 2,011 funds tracked by Wall St. Rank hold CL as of Q2 2026.
- Arax Advisory Partners held 65,662 shares of Colgate-Palmolive worth $6.02M as of Q2 2026.
- Arax Advisory Partners bought 39,249 Colgate-Palmolive shares in Q2 2026, an estimated $3.43M.
- Colgate-Palmolive made up 0.04% of Arax Advisory Partners's portfolio in Q2 2026, its #431 holding.
- Arax Advisory Partners first reported a position in Colgate-Palmolive in Q4 2016 and has held it in 37 quarters since.
- 2,011 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.